Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Cash & Equivalents (2019 - 2025)

IDEAYA Biosciences (IDYA) has disclosed Cash & Equivalents for 7 consecutive years, with $112.8 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 33.71% to $112.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $112.8 million through Dec 2025, up 33.71% year-over-year, with the annual reading at $112.8 million for FY2025, 33.71% up from the prior year.
  • Cash & Equivalents hit $112.8 million in Q4 2025 for IDEAYA Biosciences, down from $298.9 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $400.3 million in Q3 2024 to a low of $49.1 million in Q2 2022.
  • Historically, Cash & Equivalents has averaged $130.7 million across 5 years, with a median of $108.4 million in 2021.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 285.63% in 2021 and later plummeted 59.57% in 2022.
  • Year by year, Cash & Equivalents stood at $92.0 million in 2021, then fell by 25.44% to $68.6 million in 2022, then soared by 128.78% to $157.0 million in 2023, then tumbled by 46.26% to $84.4 million in 2024, then surged by 33.71% to $112.8 million in 2025.
  • Business Quant data shows Cash & Equivalents for IDYA at $112.8 million in Q4 2025, $298.9 million in Q3 2025, and $114.6 million in Q2 2025.